

VPH Institute

Building the Virtual Physiological Human



CONTRIBUTE TO MAKE IN SILICO MEDICINE A REALITY!

The Avicenna Alliance (AA) is a global association of organisations, having a commercial or research interest in the development, adoption and deployment of in silico medicine to ensure safe, affordable and cost-efficient healthcare.

The AA academic membership is represented by the VPH Institute. Thanks to this strategic asset, the VPH Institute can offer all its members the opportunity to access and contribute to all the Avicenna Alliance's activities.

Collaboration among AA members takes place through the participation of different working groups, where members share their knowledge and expertise, writing white papers, publishing case studies, organising events and establishing collaborations with regulators and policy makers all over the world.

Get an overview of the 3 working groups and related task forces of the Avicenna Alliance!

POLICY DEVELOPMENT WORKING GROUP



Emmanuelle Voisin

Founder & CEO, Voisin Consulting Life Sciences

Cécile Rousseau

Senior Director Nonclinical, Voisin Consulting Life Sciences

Ensure policy framework for deployment & acceptance of in silico technologies by competent authorities to foster medical innovation (including for rare diseases and pediatric applications) and reduce time & cost for treatment approval and reimbursement.

TASK FORCES

■ **Pharmaceutical Strategy**

Accelerate Adoption by Healthcare Stakeholders of In Silico Medicine for Bringing New Medicine to Patients.

Co-Chairs: Cécile De Coste (*Alexion*), Francesco Pappalardo (*University of Catania*)

■ **European Medicine Agency (EMA) Collaboration**

Closely collaborate with EMA to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence.

Co-Chairs: Liesbet Geris (*VPHI, U.Liège, KU Leuven*), Martha De Cunha Maluf-Burgman (*Edwards Lifesciences*)

■ **Good Simulation Practice**

Drafting a Good Simulation Practice document widely recognized and accepted similar to the Good Clinical Practice.

Co-Chairs: Luca Emili (*InSilicoTrials*), Marco Viceconti (*University of Bologna*)

■ **Public & Patient Involvement (PPI)**

Empower the public & patients to understand the potential of in silico medicine, improve healthcare creating 'user demand', encourage greater funding and drive broader clinical and regulatory adoption for enhanced impact.

Co-Chairs: Cyrille Thinnes (*NUI Galway*), Steve Levine (*Dassault Systèmes*)

■ **Notified Bodies**

Systematic engagement with NBs to advance in silico trials in Europe.

Co-Chairs: Simon Sonntag (*Virtonomy*), Bernard Staumont (*University of Liège*)

RESEARCH & TECHNOLOGY WORKING GROUP



Liesbet Geris

Executive Director, VPH Institute

Professor, University of Liège & KU Leuven (Belgium)

Bridge the missing mile between basic research and the commercialization of products and provide a unique opportunity to explore areas of mutual cooperation and benefit & cost for treatment approval and reimbursement. Run the C4Bio community challenge defining a consensus protocol for certified tissue properties.

TASK FORCES

■ **Tissue Characterization**

Create a data base of biological tissue properties with Certificate of Birth.

Co-Chairs: Venkat Perumal (*Stryker*), Nele Famaey (*KU Leuven*)

■ **Artificial Intelligence**

Engage in all AA activities related to AI.

Co-Chairs: Jérôme Noailly (*Universitat Pompeu Fabra*), Gordon Johnston (*Johnson & Johnson*)

■ **Horizon Europe**

Monitor, influence & inform on Horizon Europe Funding.

Chair: Liesbet Geris (*VPHi, U.Liège, KU Leuven*)

■ **Medical Community Outreach**

Assess & positively influence current perception of in silico technologies in medical community

Chair: Claudio Capelli (*UCL & GOSH*)

INTERNATIONAL WORKING GROUP



Mark Palmer
*Distinguished Scientist, Technical Fellow
Medtronic, PLC (Minneapolis, USA)*

Promote predictive medicine and in silico trials with global stakeholders; increase confidence in in silico evidence with global regulators; support global harmonization of guidance documents & objective standards.

TASK FORCES

■ Global Harmonization

Inform and educate regulatory agencies around the world to ensure harmonized adoption of in silico methods.

Chair: Marc Horner (*Ansys*)

■ UK In Silico Regulatory Innovation

Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations.

Co-Chairs: Alex Frangi (*University of Leeds*), David Flynn (*Boston Scientific*)

■ APAC (*in progress*)

Establish contacts with regulators in the Asian Pacific area and understand voice of "Regulatory" stakeholder as it relates to modeling & simulation and in silico medicine.

All VPHi members can contribute to these important activities. If you want to get involved, contact manager@vph-institute.org

vph-institute.org
avicenna-alliance.com



Avicenna Alliance
Association for Predictive Medicine